The wrong "war" on drugs
The AP reports:
The pharmaceutical powers cannot buy off the media apparently. Pay-offs to congresscritters have protected them against the SSRI dangers so far. Money does talk."Vioxx, launched in the United States in 1999, and a successor drug called Arcoxia, approved in some other countries and awaiting Food and Drug Administration approval here, are part of a class of anti-inflammatory drugs heavily touted by the pharmaceutical industry as being more effective and having less side effects, particularly on the gastrointestinal system, than older drugs.
Pfizer's Celebrex and its successor drug, Bextra, which already is on the market in the United States, also are in that class, called cox-2 inhibitors.
'This has never been the massive innovation which was promoted to be,' Shah said of the drug class. 'In terms of pain relief, these drugs are no better than ibuprofen and they cost 10, 15 times more.'"
Comments:
Post a Comment
Links to this post: links to this post
